

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0104				
Estimated average burder	n hours per				
	0.5				

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of

(Print or Type Responses	s)									
SEIDENBERG BETH C (Month/Day/				nth/Day/Year)			3. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]			
(Last) (First) (Middle) 2750 SAND HILL ROAD			10/15/20	10/15/2014		(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable)		5. If Amendment, Date Original Filed(Month/Day/Year)	
MENLO PARK, CA	(Street)					XDirector Officer (give title belo	X10% Owner Other (specify below)		6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person	
(City)	(State)	(Zip)				Table I - Non-Deri	vative Securities B	eneficially Owned		
1.Title of Security (Instr. 4)			2. Amount of Sec (Instr. 4)	curities Beneficially Owned		4. Nature of Indirect Beneficial Ownership				
Common Stock			746,923		I	See Footnote (1)				
Common Stock					22,307	I See Foo		See Footnote (2)	Footnote (2)	
Reminder: Report on a s	Persons	who respond to th valid OMB contro	e collection I number.	of inforn	nation containe	ed in this form are not re			SEC 1473 (7-02)	
1. Title of Derivative Se (Instr. 4)	ecurity	Table II-1		Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
			Date Expiration Exercisable Date		Title	Amount or Number of Shares				
Series A Preferred S	tock		(3)	(3)	Common Stock	1,244,871	\$ <u>(3)</u>	I	See Footnote (1)	
Series B Preferred S	tock		(3)	(3)	Common Stock	607,234	\$ (3)	I	See Footnote (1)	
Series A Preferred S	tock		(3)	(3)	Common Stock	37,179	\$ <u>(3)</u>	I	See Footnote (2)	
Series B Preferred S	tock		<u>(3)</u>	<u>(3)</u>	Common	18,136	\$ <u>(3)</u>	I	See Footnote (2)	

Reporting Owners

Reporting Owner Name / Address	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
SEIDENBERG BETH C 2750 SAND HILL ROAD MENLO PARK, CA 94025	X	X			

Signatures

/s/ Paul Vronsky, Attorney-in-Fact	10/15/2014		
Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares are directly held by Kleiner Perkins Caufield & Byers XV, LLC ("KPCB XV"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XV is KPCB a dispositive control over the shares is shared by the managing members of XV Associates and the Reporting Person.
- (2) The shares are directly held by KPCB Founders Fund, LLC ("KPCB XV FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XV FF is XV Associates, or by the managing members of XV Associates and the Reporting Person.
- (3) Each share of Series A Preferred Stock and Series B Preferred Stock is convertible into one share of Common Stock without payment of further consideration and will automatically convert into one share of Common Stock upon have no expiration date.

Remarks:

The Reporting Person disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Beth Seidenberg, M.D. (the "Reporting Person") hereby authorizes and designates Susan Biglieri, Paul Vronsky and Eric Keller (each, an "Authorized Signatory") to prepare and file on behalf of the Reporting Person individually, or jointly together with the other reporting persons, any and all reports, notices, communications and other documents (including, but not limited to, reports on Schedule 13D, Schedule 13G, Form 13-F, Form 3, Form 4 and Form 5) that the Reporting Person may be required to file with the United States Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (together with the implementing regulations thereto, the "Act") and the Securities Exchange Act of 1934, as amended (together with the implementing regulations thereto, the "Exchange Act") (collectively, the "Reports") with respect to the Reporting Person's ownership of, or transactions in, securities of any entity whose securities are beneficially owned (directly or indirectly) by the Reporting Person (collectively, the "Companies"). The Reporting Person hereby further authorizes and designates each Authorized Signatory to perform any and all other acts, which in the opinion of such Authorized Signatory may be necessary or incidental to the performance of the foregoing powers herein granted.

The authority of each Authorized Signatory under this Document with respect to the Reporting Person shall continue until the Reporting Person is no longer required to file any Reports with respect to the Reporting Person's ownership of, or transactions in, the securities of the Companies, unless earlier revoked in writing. The Reporting Person acknowledges that each Authorized Signatory is not assuming any of the Reporting Person's responsibilities to comply with the Act or the Exchange Act.

June 26, 2012

/s/ Beth Seidenberg, M.D. Beth Seidenberg, M.D.